Lee's Pharmaceutical Holdings Limited (LPCUF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lee's Pharmaceutical Holdings Limited (LPCUF) trades at $0.19 with AI Score 54/100 (Grade B). Lee's Pharmaceutical Holdings Limited develops, manufactures, and markets pharmaceutical products, primarily in China. Market cap: $112.06M, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for LPCUF: LPCUF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LPCUF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
LPCUF: 1/4 perspectives are bullish. Dominant signal: Seth Klarman bullish.
Lee's Pharmaceutical Holdings Limited (LPCUF) Healthcare & Pipeline Overview
Lee's Pharmaceutical Holdings Limited focuses on developing, manufacturing, and marketing pharmaceutical products in China, addressing cardiovascular diseases, women's health, and oncology. With a diverse portfolio of proprietary, generic, and licensed-in products, the company maintains a presence in a competitive market, demonstrating a modest profit margin and dividend yield.
What Is the Investment Thesis for LPCUF?
Lee's Pharmaceutical Holdings Limited presents an investment case centered on its established presence in the Chinese pharmaceutical market and its diverse product portfolio. With a market capitalization of $0.11 billion and a P/E ratio of 8.13, the company demonstrates potential value. A gross margin of 53.1% indicates efficient operations. Growth catalysts include expanding its portfolio of licensed-in products and penetrating deeper into specialized therapeutic areas like oncology and rare diseases. The company's dividend yield of 3.48% may attract income-focused investors. However, potential risks include navigating the complex regulatory landscape in China and competition from both domestic and international pharmaceutical companies. The company's beta of 0.50 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
LPCUF Key Highlights
- Market capitalization of $0.11 billion indicates its current size and valuation within the pharmaceutical industry.
- P/E ratio of 8.13 suggests a potentially undervalued stock compared to its earnings.
- Gross margin of 53.1% reflects efficient cost management in product development and manufacturing.
- Dividend yield of 3.48% provides a steady income stream for investors.
- Beta of 0.50 indicates lower volatility compared to the overall market, potentially offering a more stable investment.
Who Are LPCUF's Competitors?
LPCUF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADOIF Adocia S.A. | $8.87 | +0.00% | 104M | 52 |
| AMEUF Anteris Technologies Ltd | $5.70 | -35.81% | $120.50M | 57 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| COPHF Creso Pharma Limited | $0.12 | +0.00% | $131.72M | 56 |
| DIUXF Diaceutics PLC | $2.00 | +0.00% | $169.26M | 59 |
| ALVO Alvotech | $4.44 | +5.21% | $1.39B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LPCUF's Key Strengths?
- Diverse product portfolio across multiple therapeutic areas.
- Established presence in the Chinese pharmaceutical market.
- Partnerships with international pharmaceutical companies for licensed-in products.
- Focus on specialized therapeutic areas with high growth potential.
What Are LPCUF's Weaknesses?
- Reliance on licensed-in products may limit control over product development and pricing.
- Exposure to regulatory risks in the Chinese pharmaceutical market.
- Limited brand recognition compared to larger multinational pharmaceutical companies.
- Smaller market capitalization compared to major competitors.
What Could Drive LPCUF Stock Higher?
- Expansion of the licensed-in product portfolio, driving revenue growth and market share.
- Increasing sales of proprietary and generic products through expanded marketing efforts.
- Penetration into specialized therapeutic areas such as oncology and rare diseases.
- Potential regulatory approvals for new pharmaceutical products in China.
- Expansion of geographic reach within China, particularly in underserved regions.
What Are the Key Risks for LPCUF?
- Intense competition from domestic and international pharmaceutical companies.
- Pricing pressures from government regulations and healthcare reforms in China.
- Patent expirations and generic competition for key products.
- Changes in regulatory requirements and approval processes in China.
- Reliance on licensed-in products may limit control over product development and pricing.
What Are the Growth Opportunities for LPCUF?
- Expanding the portfolio of licensed-in products: Lee's Pharma can drive growth by acquiring rights to market and sell innovative drugs developed by international pharmaceutical companies. This strategy allows the company to quickly expand its product offerings and address unmet medical needs in China. The market for licensed-in pharmaceuticals is expected to grow as international companies seek to enter the Chinese market. Timeline: Ongoing.
- Penetrating deeper into specialized therapeutic areas: By focusing on niche markets such as oncology, rare diseases, and women's health, Lee's Pharma can achieve higher margins and establish a competitive advantage. These therapeutic areas often have less competition and higher unmet needs. The market for specialized drugs is growing rapidly due to advances in medical research and increasing awareness of rare diseases. Timeline: Ongoing.
- Increasing sales of proprietary and generic products: Lee's Pharma can drive organic growth by expanding its sales and marketing efforts for its self-developed and generic pharmaceutical products. This includes increasing its presence in hospitals, pharmacies, and online channels. The market for generic drugs in China is expected to grow as the government promotes their use to reduce healthcare costs. Timeline: Ongoing.
- Expanding geographic reach within China: Lee's Pharma can expand its presence in underserved regions of China, particularly in rural areas where access to healthcare is limited. This includes establishing new sales offices, distribution centers, and partnerships with local healthcare providers. The market for pharmaceuticals in rural China is growing rapidly as the government invests in improving healthcare infrastructure. Timeline: Ongoing.
- Leveraging digital marketing and e-commerce channels: Lee's Pharma can leverage digital marketing and e-commerce channels to reach a wider audience and increase sales of its products. This includes developing online pharmacies, partnering with e-commerce platforms, and using social media to promote its products. The market for online pharmaceuticals in China is growing rapidly as consumers increasingly prefer to purchase healthcare products online. Timeline: Ongoing.
What Opportunities Does LPCUF Have?
- Expanding into underserved regions of China with growing healthcare demand.
- Increasing investment in research and development to develop proprietary products.
- Leveraging digital marketing and e-commerce channels to reach a wider audience.
- Acquiring smaller pharmaceutical companies to expand product portfolio and market share.
What Threats Does LPCUF Face?
- Increasing competition from domestic and international pharmaceutical companies.
- Pricing pressures from government regulations and healthcare reforms.
- Patent expirations and generic competition for key products.
- Changes in regulatory requirements and approval processes.
What Are LPCUF's Competitive Advantages?
- Established presence in the Chinese pharmaceutical market.
- Diverse product portfolio of proprietary, generic, and licensed-in products.
- Focus on specialized therapeutic areas with less competition.
- Strong relationships with international pharmaceutical companies for licensing agreements.
What Does LPCUF Do?
Founded in 1994 and headquartered in Sha Tin, Hong Kong, Lee's Pharmaceutical Holdings Limited has established itself as a player in the Chinese pharmaceutical market. The company operates as an investment holding entity, focusing on the development, manufacturing, marketing, and sales of pharmaceutical products. Lee's Pharma addresses a spectrum of therapeutic areas, including cardiovascular diseases, women's health, pediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. The company operates through two primary segments: Proprietary and Generic Products, and Licensed-In Products. The Proprietary and Generic Products segment focuses on self-developed and generic pharmaceutical products, including treatments for blood clots, viral infections, hemostasis, corneal ulcers, and pulmonary arterial hypertension. The Licensed-In Products segment trades in pharmaceutical products licensed from other companies, offering treatments for carnitine deficiency, chemotherapy-induced nausea and vomiting, immunosuppression, and various other conditions. These products are sourced from international partners, expanding the company's portfolio and market reach within China. Lee's Pharmaceutical Holdings Limited aims to provide a diverse range of pharmaceutical solutions to address unmet medical needs in its target markets.
What Products and Services Does LPCUF Offer?
- Develops proprietary pharmaceutical products.
- Manufactures generic pharmaceutical products.
- Markets and sells pharmaceutical products in China.
- Licenses-in pharmaceutical products from international companies.
- Focuses on therapeutic areas like cardiovascular, women's health, and oncology.
- Offers treatments for rare diseases and other specialized conditions.
- Operates through proprietary/generic and licensed-in product segments.
How Does LPCUF Make Money?
- Develops and manufactures proprietary pharmaceutical products for sale in China.
- Licenses pharmaceutical products from international companies and markets them in China.
- Generates revenue through the sale of pharmaceutical products to hospitals, pharmacies, and other healthcare providers.
- Focuses on specialized therapeutic areas to achieve higher margins and competitive advantage.
What Industry Does LPCUF Operate In?
Lee's Pharmaceutical Holdings Limited operates within the competitive Chinese pharmaceutical market, which is characterized by increasing demand for specialized and generic drugs. The market is driven by an aging population, rising healthcare expenditure, and government initiatives to improve access to healthcare. The company faces competition from both domestic players and multinational pharmaceutical companies. Key industry trends include the growing importance of innovative drugs, the increasing adoption of generics, and the evolving regulatory landscape. Lee's Pharma's focus on specialized therapeutic areas and its strategy of licensing-in products position it to capitalize on these trends.
Who Are LPCUF's Key Customers?
- Hospitals and clinics throughout China.
- Pharmacies and drug stores.
- Healthcare providers.
- Patients requiring specialized pharmaceutical treatments.
LPCUF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
LPCUF Latest News
No recent news available for LPCUF.
LPCUF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LPCUF.
Price Targets
Wall Street price target analysis for LPCUF.
LPCUF MoonshotScore
What does this score mean?
The MoonshotScore rates LPCUF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Siu Fong Lee
CEO
Siu Fong Lee serves as the CEO of Lee's Pharmaceutical Holdings Limited. Information regarding Mr. Lee's detailed background, including his educational qualifications and previous roles, is not available in the provided data. However, as the CEO, he is responsible for the overall strategic direction and operational management of the company, guiding its growth and expansion in the Chinese pharmaceutical market.
Track Record: As the CEO of Lee's Pharmaceutical Holdings Limited, Siu Fong Lee has overseen the company's operations and strategic initiatives. Specific achievements and milestones under his leadership are not detailed in the provided data. However, his role involves guiding the company's focus on developing, manufacturing, and marketing pharmaceutical products, as well as managing its relationships with international partners for licensed-in products.
LPCUF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lee's Pharmaceutical Holdings Limited may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, and the availability of information may be restricted. Investing in companies on the OTC Other tier carries higher risks compared to those listed on major exchanges like the NYSE or NASDAQ, due to less stringent listing standards and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry and makes it difficult to assess the company's financial health.
- Lower trading volume and wider bid-ask spreads can lead to increased volatility and execution risk.
- OTC stocks are subject to less regulatory oversight, increasing the risk of fraud and mismanagement.
- The OTC Other tier indicates that the company may not meet minimum financial or operational standards.
- Potential for delisting or trading suspension due to non-compliance with OTC market rules.
- Verify the company's registration and regulatory filings.
- Obtain and review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- The company has been in operation since 1994, indicating a long-term presence in the pharmaceutical market.
- Lee's Pharma has a diverse product portfolio of proprietary, generic, and licensed-in products.
- The company focuses on specialized therapeutic areas with high growth potential.
- Lee's Pharma has partnerships with international pharmaceutical companies for licensed-in products.
LPCUF Healthcare Stock FAQ
What does Lee's Pharmaceutical Holdings Limited do?
Lee's Pharmaceutical Holdings Limited is a pharmaceutical company that develops, manufactures, markets, and sells pharmaceutical products, primarily in China. The company operates through two segments: Proprietary and Generic Products, which focuses on self-developed and generic drugs, and Licensed-In Products, which involves trading in licensed pharmaceuticals from international partners. They address various therapeutic areas, including cardiovascular diseases, women's health, pediatrics, rare diseases, and oncology, offering a diverse range of treatments to meet medical needs in the Chinese market.
What are the main risks for LPCUF?
Lee's Pharmaceutical Holdings Limited faces several risks, including intense competition from both domestic and international pharmaceutical companies in China. Pricing pressures from government regulations and healthcare reforms could impact profitability. The company's reliance on licensed-in products exposes it to potential disruptions in supply or changes in licensing agreements. Patent expirations and generic competition for key products could erode market share. Changes in regulatory requirements and approval processes in China could delay or prevent the launch of new products.
What are the key factors to evaluate for LPCUF?
Lee's Pharmaceutical Holdings Limited (LPCUF) holds an AI score of 54/100 (moderate). Not financial advice.
How frequently does LPCUF data refresh on this page?
LPCUF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LPCUF's recent stock price performance?
Lee's Pharmaceutical Holdings Limited (LPCUF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LPCUF overvalued or undervalued right now?
Valuing Lee's Pharmaceutical Holdings Limited (LPCUF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LPCUF?
Before investing in Lee's Pharmaceutical Holdings Limited (LPCUF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LPCUF to a portfolio?
Key strength of Lee's Pharmaceutical Holdings Limited (LPCUF): Diverse product portfolio across multiple therapeutic areas. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.